First, we compared the expression levels of E2F2 and E2F8 in the BVZ-responsive subtypes of recurrent patients, as shown in Figure 6E. In BVZ-responsive GBM patients, the expression levels of E2F2 and E2F8 increased by approximately 2-fold and 6.5-fold, respectively, after BVZ treatment. The gene discussed is E2F8; the disease is glioblastoma.